Making medical decisions is not as easy as following the evidence. When dealing with people, there are a number of anomalies that influence the decisions someone might make.
Making medical decisions is not as easy as following the evidence. When dealing with people, there are a number of anomalies that influence the decisions someone might make, explained Douglas E. Hough, PhD, from Johns Hopkins University, during a plenary session at ISPOR’s annual meeting.
Hough outlined the thought processes that impact someone’s decisions or behaviors and the implications behavioral economics could have in healthcare. He provided 5 examples of anomalies that influence behavior:
These all influence things in healthcare, such as how we fight obesity, how adherent we are to medication, physician engagement and hand offs in the emergency room, and more, Hough concluded.
Kevin Volpp, MD, PhD, of the University of Pennsylvania, discussed the 5000-hour problem, whereby even for patients with a chronic illness who see their doctor multiple times a year, there are 5000-plus hours where these patients are largely on their own. Technology is creating an enormous opportunity for population health, but it cannot work on its own.
“While the technology creates enormous new opportunities in this space, just giving people these devices by themselves is unlikely to change their behavior,” he said. “People who buy these [devices] are typically those who are already motivated and thinking about their health.”
The devices need to be part of a larger ecosystem where patients have a device that uploads information to a health system’s services and either the patient or a social supporter and the provider gets feedback and the information goes into the electronic medical record.
What will ultimately drive change, though? The relationship, said David Meltzer, MD, PhD, of University of Chicago. The literature on patient-doctor relationships has shown the importance of trust, interpersonal relationships, communication, and knowledge of the patient in the form of lower costs and better outcomes.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More